RBC Europe’s Heron Therapeutics HRTX Stock Holding History

RBC Europe’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-120	Closed	-$1.28K	–	851
2021 Q3	$1.28K	Hold	120	–	–	﹤0.01%	1167
2021 Q2	$1.86K	Hold	120	–	–	﹤0.01%	1133
2021 Q1	$1.95K	Hold	120	–	–	﹤0.01%	1080
2020 Q4	$2.54K	Hold	120	–	–	﹤0.01%	1032
2020 Q3	$1.78K	Hold	120	–	–	﹤0.01%	996
2020 Q2	$1.76K	Hold	120	–	–	﹤0.01%	962
2020 Q1	$1.41K	Buy	+120	New	+$2.26K	﹤0.01%	937

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

RBC Europe's HRTX Position: Q4 2021 in Review

RBC Europe sold out of Heron Therapeutics (HRTX) in Q4 2021, closing a stake of 120 shares — an estimated $1.28K sold.

RBC Europe first reported a position in HRTX in Q1 2020 and held it in 7 quarters. The position peaked at $2.54K in Q4 2020. 200 funds tracked by Wall St. Rank hold HRTX as of Q4 2021.

RBC Europe reported no remaining Heron Therapeutics position as of Q4 2021 after selling out during the quarter.
RBC Europe sold 120 Heron Therapeutics shares in Q4 2021, an estimated $1.28K.
RBC Europe first reported a position in Heron Therapeutics in Q1 2020 and held it in 7 quarters.
RBC Europe's Heron Therapeutics position peaked at $2.54K in Q4 2020.
200 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.